Support for Legal Marijuana Higher Than Ever
The industry on cannabis has become one of the fastest growing industries across the nation over the last several years. With new markets growing in and around the U.S., many polls are reporting that support for cannabis use and legalization, is higher than ever before. One of the major... Read more
Tetra Bio-Pharma Inc (TBPMF) Evidence-Based Business Model Confirmed
Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra... Read more
Hemp, Inc. (HEMP) Commends U.S. Senate for Passing Farm Bill
Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with the largest multipurpose industrial hemp processing facility in the western hemisphere, announced today the company commends the U.S. Senate for passing the 2018 Farm Bill in a 86-11 vote, yesterday June 28, 2018. Bruce Perlowin, CEO of Hemp,... Read more
Aphria Inc. (APHQF) Signs Supply Agreement with MBLL
Aphria Inc. (“Aphria” or the “Company“) (TSX: APH and US OTC: APHQF) today announced that it has signed a Supply Agreement (the “Agreement“) with the Manitoba Liquor and Lotteries Corporation(“MBLL“) to provide a portfolio of high-quality, branded cannabis and cannabis derivative products for sale in Manitoba’s adult-use market. “We are thrilled... Read more
Lexaria Bioscience Corp. (LXRP) New Patent Application for Enhancement of Delivery of Lipophilic Agents
In recent laboratory testing, Lexaria’s breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECHTM than concentration-matched controls lacking DehydraTECHTM enhancements. The study provided evidence of surprising effectiveness in crossing the blood-brain barrier (“BBB”) which the... Read more
Organigram Holdings Inc. (OGRMF) signs supply agreement with Manitoba Liquor & Lotteries
Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of medical marijuana based in Moncton, New Brunswick , is pleased to announce that it has been approved as a supplier of cannabis for the province of Manitoba... Read more
Namaste Technologies Inc. (NXTTF) signs Master Services Agreement with Australian-based YPB
Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV:N.V)(M5BQ.F)(NXTTF) is pleased to announce signing of a Master Services Agreement (the “Agreement”) with YPB Group Ltd. (“YPB”)(YPB.AX), an Australian based product verification and customer engagement company. Namaste has identified the need for its global customers to have confidence in the products... Read more
The Biggest Cannabis Stocks in the Industry Continue to Grow
The marijuana market has continued to show a large amount of promise over the course of the past year or so. With new legislation going into place around North America and the world, it seems as though the cannabis industry is just now getting started. Momentum during the past... Read more
Leafbuyer Technologies, Inc. (LBUY) Reports Explosive Traffic Growth of 375% for Last 12 Months
Leafbuyer Technologies, Inc. (LBUY) (“Leafbuyer”), a leading cannabis technology platform, announced today that it has reported annual website traffic growth to Leafbuyer.com of 375%. Leafbuyer’s new session numbers also grew nearly 30% from March 2018. The growth comes after the company rolled out its new product directory and added major search functionality... Read more
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced positive top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries. At the... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )